Genmab A/S (GMAB) News Today $33.25 -0.31 (-0.91%) As of 09:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GMAB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Genmab A/S (NASDAQ:GMAB) Upgraded to Strong-Buy at Zacks ResearchOctober 4 at 6:01 AM | marketbeat.comWhy Genmab Stock Popped on FridayOctober 3 at 6:00 PM | fool.comGenmab A/S (NASDAQ:GMAB) Price Target Raised to $40.00October 3 at 3:17 AM | americanbankingnews.comFY2025 EPS Estimates for Genmab A/S Raised by William BlairOctober 3 at 2:31 AM | americanbankingnews.comGenmab price target raised to $40 from $36 at H.C. WainwrightOctober 2, 2025 | msn.comHC Wainwright Issues Positive Forecast for Genmab A/S (NASDAQ:GMAB) Stock PriceOctober 2, 2025 | marketbeat.comLeerink Partnrs Comments on Genmab A/S FY2027 EarningsOctober 2, 2025 | marketbeat.comTD Cowen Remains a Hold on Genmab (GMAB)October 2, 2025 | theglobeandmail.comFY2025 EPS Estimates for Genmab A/S Boosted by William BlairOctober 1, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Sees Large Volume Increase on Analyst UpgradeOctober 1, 2025 | americanbankingnews.comGenmab A/S Updates Articles of Association to Enhance Growth StrategySeptember 30, 2025 | msn.comMERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUSSeptember 30, 2025 | businesswire.comGenmab A/S (NASDAQ:GMAB) Sets New 52-Week High - What's Next?September 30, 2025 | marketbeat.comGenmab A/S (GMAB) Merus N.V. - M&A Call - SlideshowSeptember 30, 2025 | seekingalpha.comGenmab A/S (GMAB) M&A Call TranscriptSeptember 29, 2025 | seekingalpha.comGenmab Strikes $8 Billion Deal To Acquire Cancer-Focused MerusSeptember 29, 2025 | msn.comGenmab Makes A Big Bet With Merus N.V. AcquisitionSeptember 29, 2025 | seekingalpha.comGenmab A/S (NASDAQ:GMAB) Sees Large Volume Increase After Analyst UpgradeSeptember 29, 2025 | marketbeat.comThis Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.September 29, 2025 | barrons.comGenmab to buy Dutch cancer drugmaker Merus for $8 billionSeptember 29, 2025 | reuters.comGenmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned ModelSeptember 29, 2025 | businesswire.comGenmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned ModelSeptember 29, 2025 | globenewswire.comGenmab A/S (NASDAQ:GMAB) Upgraded to "Strong-Buy" at Wall Street ZenSeptember 27, 2025 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Stock Rating Upgraded by Wall Street ZenSeptember 26, 2025 | marketbeat.comGrant of Restricted Stock Units and Warrants to Employees in GenmabSeptember 25, 2025 | globenewswire.comGenmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2025 TranscriptSeptember 25, 2025 | seekingalpha.comGenmab A/S (NASDAQ:GMAB) Rating Increased to Buy at GuggenheimSeptember 25, 2025 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Reaches New 12-Month High Following Analyst UpgradeSeptember 25, 2025 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Sets New 52-Week High Following Analyst UpgradeSeptember 23, 2025 | marketbeat.comMajor Shareholder AnnouncementSeptember 23, 2025 | globenewswire.comGenmab A/S (NASDAQ:GMAB) Upgraded by Guggenheim to Buy RatingSeptember 23, 2025 | marketbeat.comGenmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 21, 2025 | marketbeat.comGenmab Transitioning To A Global Oncology Powerhouse: Why I Choose To BuySeptember 14, 2025 | seekingalpha.comForesight Group Ltd Liability Partnership Buys Shares of 48,725 Genmab A/S Sponsored ADR $GMABSeptember 13, 2025 | marketbeat.comGenmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent CliffSeptember 12, 2025 | seekingalpha.comGenmab: A Matter Of TimeSeptember 12, 2025 | seekingalpha.comVident Advisory LLC Purchases Shares of 12,377 Genmab A/S Sponsored ADR $GMABSeptember 12, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Hits New 52-Week High - Still a Buy?September 11, 2025 | marketbeat.comGenmab A/S Sponsored ADR $GMAB Shares Acquired by Scientech Research LLCSeptember 11, 2025 | marketbeat.comGenmab A/S (GMAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsSeptember 9, 2025 | globenewswire.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseSeptember 9, 2025 | globenewswire.comNorthern Trust Corp Purchases 25,732 Shares of Genmab A/S Sponsored ADR $GMABSeptember 7, 2025 | marketbeat.comAlliancebernstein L.P. Sells 210,066 Shares of Genmab A/S Sponsored ADR $GMABSeptember 6, 2025 | marketbeat.comGraham Capital Management L.P. Buys 16,035 Shares of Genmab A/S Sponsored ADR $GMABSeptember 5, 2025 | marketbeat.comGenmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R ...September 3, 2025 | finance.yahoo.comAbbVie updates mid-stage trial data for Genmab-partnered lymphoma drug in outpatient settingSeptember 3, 2025 | seekingalpha.comGenmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)September 3, 2025 | globenewswire.comCubist Systematic Strategies LLC Buys 665,893 Shares of Genmab A/S Sponsored ADR $GMABSeptember 2, 2025 | marketbeat.comGenmab A/S Sponsored ADR $GMAB Stake Increased by Orbis Allan Gray LtdSeptember 1, 2025 | marketbeat.com Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMAB Media Mentions By Week GMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GMAB News Sentiment▼0.620.54▲Average Medical News Sentiment GMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GMAB Articles This Week▼237▲GMAB Articles Average Week Get the Latest News and Ratings for GMAB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Genmab A/S and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Takeda Pharmaceutical News Today argenex News Today BeOne Medicines News Today Insmed News Today BioNTech News Today Teva Pharmaceutical Industries News Today Summit Therapeutics News Today Ascendis Pharma A/S News Today Dr. Reddy's Laboratories News Today Viatris News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GMAB) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
